Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
about
Hepatitis B virus therapy: What's the future holding for us?The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide AnalogsThe Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis BDirect acting antivirals for the treatment of chronic viral hepatitisSusceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitorsThe polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistanceAntiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virusPotent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virusMechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavirClinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.Recent advances in antiviral therapy.Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy.The HBV drug entecavir - effects on HIV-1 replication and resistanceStudy on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method.Postexposure prophylactic effect of hepatitis B virus (HBV)-active antiretroviral therapy against HBV infection.Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymeraseEntecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B.Changes in Mitochondrial Toxicity in Peripheral Blood Mononuclear Cells During Four-Year Administration of Entecavir Monotherapy in Chinese Patients with Chronic Hepatitis BGenetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog.Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis BAdherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with LamivudineThe amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir.Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.Antiviral resistance and hepatitis B therapy.Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in ChinaThe anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patientsPerformance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B.Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.Inhibition of hepatitis B virus polymerase by entecavir.Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China.A robust cell culture system supporting the complete life cycle of hepatitis B virus.
P2860
Q26774198-4DA43936-37E1-4074-84A9-55B8CD35281CQ26781795-A7A7745F-91BB-4F38-97DA-ED9CFF10474BQ27007019-85F41F07-AE0F-459B-A59D-D8ED586A7BA0Q27022216-F920C960-A13B-4B63-A79F-CC5BA3CAF12FQ28343399-0690E56F-A8F8-440B-A7FF-FA8846A5E7E8Q28350136-33A78E64-3C56-42D5-AB1A-326B1F7F09D8Q28360714-43919D7B-CC9D-49B5-989C-383639FD1D29Q28366818-AE70E495-5A0F-4796-8277-4BA6C22488D3Q28369473-81F421DB-ED0D-4DB9-8691-D9C638C327E8Q28748931-DDFB0CD5-AABC-494B-8FBC-1C4F92B3C821Q33206221-0BBC9FDC-733A-495E-9658-EBB7A12B1E53Q33681664-1D3FC95F-7D47-4926-9D7B-64B008381801Q33981009-37256CDD-99D2-4C13-8759-F951B541868DQ34130388-0A3793A2-F84E-41B5-861E-436E2999CE09Q34639926-AF24913A-1F36-4E7E-8FFF-93A7B7118EFEQ35001215-C594DAFB-3C86-422A-BE03-ED211F57D6ADQ35105851-18AD9DFB-DC36-45F1-BFE3-9F451E2F3E5EQ35139402-44478CCD-5DF4-40EF-9159-C16C36CBA3C8Q35166065-FCEF1AA9-E110-4AD0-8E81-4322ED7C8B5BQ35567341-413C9752-3A61-4834-8ED0-6241455B8184Q35891653-D860BA12-7F17-4A19-941F-C118E401EB9EQ35901801-858BAE2B-4B18-4E2C-B560-B8FBBE1D3636Q36615961-030F66DC-B121-4532-86B1-5A0D0BCB19DCQ36713419-C1A7BD46-AF70-4335-9229-89650E0410A0Q37099820-902B9AD8-A592-448A-8959-A02803078CBEQ37124000-D2C43A4F-A718-4C38-80E4-E23F05558BCAQ37255008-420BAA22-5BAC-4A77-AC9F-82D2E9FA9C9BQ37278075-2227BF86-0E2F-4D3A-922C-B99FD3D397C5Q37293650-8552A149-9F1C-4F83-AA76-98670759FC02Q37488838-B0207689-A2D3-452C-A34D-B12BDD81A091Q39277056-69E9786B-F964-40DB-BD85-2B6E0FEBEB34Q39559675-C98F12BB-D49B-4AA2-9A5E-E2E9E43670BEQ39559680-3691C377-2ECF-472D-9178-32B70A7CD8EEQ39652624-EDB401A9-6C36-4FD0-9C01-998136A02534Q40006328-3A19A28D-39A8-4FCE-B9A5-92E0BF09519BQ40164099-CC1D7C86-7571-45A1-AC6D-417CF1686B88Q40176633-C92C5DA9-CF82-4E4F-8468-B2281AD9F825Q41883516-3F21E3D8-B046-4AA5-B974-7491A5FAEBC6Q42044622-E6DE6FE0-D76C-43F6-A62F-AF5CA46FAFDCQ45323970-5E95650A-4234-4B98-969F-6FA8D525F352
P2860
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
description
1997 nî lūn-bûn
@nan
1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
@ast
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
@en
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
@nl
type
label
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
@ast
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
@en
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
@nl
prefLabel
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
@ast
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
@en
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
@nl
P2093
P2860
P1476
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
@en
P2093
D N Standring
G S Bisacchi
R J Colonno
S F Innaimo
P2860
P304
P407
P577
1997-07-01T00:00:00Z